Home/Pipeline/RMA (cMYc targeting)

RMA (cMYc targeting)

MYC‑amplified cancers

PreclinicalActive

Key Facts

Indication

MYC‑amplified cancers

Phase

Preclinical

Status

Active

Company

Eloxx Pharmaceuticals

About Eloxx Pharmaceuticals

Ribosome‑targeted small‑molecule platform for rare genetic diseases and cancer.

View full company profile

Therapeutic Areas

Rare Genetic Diseases Oncology